BASEL, SWITZERLAND--(MARKET WIRE)--Sep 28, 2007 -- Basilea Pharmaceutica Ltd. (Swiss:BSLN.SW - News) announced today the submission of a marketing authorization application to Swissmedic for its investigational drug alitretinoin. The submission supports the proposed use of oral alitretinoin in severe refractory chronic hand eczema. Basilea also announced the appointment of Mr. Hans Christian Rohde as Global Head of Commercial Operations.
